alexa Tumor senescence as a determinant of drug response in vivo.


Journal of Carcinogenesis & Mutagenesis

Author(s): Roninson IB

Abstract Share this page

Abstract It has become apparent in the last few years that induction of apoptosis is insufficient to account for the therapeutic effect of anticancer agents. Chemotherapy and radiation induce two other antiproliferative responses in tumor cells, cell death through mitotic catastrophe and terminal growth arrest through the program of senescence. Different types of tumor cells were found to develop the senescent phenotype upon drug treatment in vitro and in vivo. Cell culture studies demonstrated that this phenotype marks tumor cells that survive drug exposure but lose the ability to proliferate, and that such cells activate multiple growth-inhibitory genes. A recent study demonstrated that senescence, along with apoptosis, is a key determinant of in vivo response to chemotherapy in a transgenic mouse model of B-cell lymphoma. This review discusses the results of the latter study, as well as the differences between the genetic determinants of treatment-induced senescence in murine lymphoma and in human solid tumor cells.
This article was published in Drug Resist Updat and referenced in Journal of Carcinogenesis & Mutagenesis

Relevant Expert PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version